Veracyte Inc (FRA:12V)
€ 32 0.6 (1.91%) Market Cap: 2.54 Bil Enterprise Value: 2.34 Bil PE Ratio: 0 PB Ratio: 2.37 GF Score: 83/100

Veracyte Inc at Credit Suisse Healthcare Conference Transcript

Nov 08, 2022 / 06:25PM GMT
Release Date Price: €24.36 (+0.77%)
Unidentified Analyst

So in our next session, we have Veracyte, Marc Stapley, CEO; Rebecca Chambers, CFO. Thank you both for joining us. I'm Dan Leonard, the diagnostics analyst at Credit Suisse and happy to kick things off and learn more about Veracyte.

Marc, I think you wanted to start with the safe harbor statement?

Marc A. Stapley
Veracyte, Inc. - CEO & Director

Yes. Thanks, Dan, and thanks for having us here today. It's a real pleasure to be here at this conference. And yes, I would like to refer investors to our safe harbor statement that can be found on our corporate website, in our corporate presentation, www.veracyte.com, to the extent we make forward-looking statements that are intended to be covered by the safe harbor statement.

Questions & Answers

Unidentified Analyst

Look forward to that. So before we get off and start talking about forward-looking statements, Marc, can you give us a brief overview of Veracyte for folks who aren

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot